M2Bio Sciences (Wuhan General Group) has finalized an agreement with the University of Pretoria (South Africa) to conduct a psilocybin-based clinical trial.
Psychedelics
Hapbee to Commence Trading on the TSX Venture Exchange Under the Ticker Symbol "HAPB"
Fitness wearables company, Hapbee Technologies, is going to commence trading October 30th on the TSX Venture Exchange (symbol "HAPB").
Huge Cost-Savings From Psychedelic Drug Therapy
MAPS' recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.
MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp.
Entheon Biomedical has received conditional approval from the CSE to commence public trading.
MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.
The 4 Best-Performing Psychedelic Stocks
As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.
How and Why Psychedelic Drugs Can Conquer The Mental Health Crisis
An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
Field Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago
Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.
Mind Cure’s New Medtech Platform Is A Critical Puzzle-Piece
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
Psyched Wellness Ltd. to Commence Trading on the CSE on October 22, 2020
The latest psychedelic drug company to commence public trading is Psyched Wellness.
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Parkinson's Disease
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
Why Psychedelic Stocks Are A Strong Hedge Against COVID-19 Risk
Psychedelic drug stocks may represent the best investing strategy to hedge against COVID-19 economic risks.
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.